Related Experiment Video

Updated: Jun 11, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

BANF1 knockdown impedes thyroid cancer development and boosts CD8+ T cell activity through PI3K/AKT/mTOR pathway

Chuanbing Liu1, Zhen Jia1, Dan Wei1

  • 1Department of Endocrinology and Metabolism, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Institute of Nephrology Jinan, Shandong, China.

American Journal of Cancer Research
|June 10, 2026
PubMed

Insights

Barrier to Autointegration Factor 1 (BANF1) is elevated in thyroid cancer, suppressing tumor growth and enhancing CD8+ T cell immunity via the PI3K/AKT/mTOR pathway.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Immunology

Background:

  • Barrier to Autointegration Factor 1 (BANF1) is an evolutionarily conserved DNA-binding protein implicated in various diseases.
  • Dysregulation of BANF1 is linked to disease development, prompting investigation into its role in specific cancers.

Purpose of the Study:

  • To investigate the role of BANF1 in thyroid cancer progression.
  • To determine the impact of BANF1 on tumor immunity, specifically CD8+ T cell responses.
  • To elucidate the underlying molecular mechanisms, including the PI3K/AKT/mTOR pathway.

Main Methods:

  • BANF1 expression analyzed by Western blot and RT-qPCR.
  • Thyroid cancer cell progression assessed via colony formation, EdU, Transwell, and Flow Cytometry (FCM).
  • CD8+ T cell viability and cytokine secretion evaluated using CCK-8 and FCM assays; PI3K/AKT/mTOR pathway proteins analyzed.

Main Results:

  • BANF1 expression is significantly higher in thyroid cancer tissues than adjacent tissues.
  • BANF1 inhibition induced apoptosis and suppressed cancer cell proliferation, migration, and invasion.
  • BANF1 knockdown enhanced CD8+ T cell proliferation and cytokine production, activating the PI3K/AKT/mTOR pathway.

Conclusions:

  • BANF1 knockdown suppresses thyroid cancer cell progression.
  • BANF1 inhibition enhances CD8+ T cell vitality and function.
  • Modulation of the PI3K/AKT/mTOR pathway is implicated in BANF1's effects on thyroid cancer and immunity.
Keywords:
BANF1CD8+ T cellsexpressionmalignant progressionthyroid cancer

More Related Videos

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...